BG64706B1 - Елетриптан хидробромид монохидрат - Google Patents

Елетриптан хидробромид монохидрат Download PDF

Info

Publication number
BG64706B1
BG64706B1 BG105539A BG10553901A BG64706B1 BG 64706 B1 BG64706 B1 BG 64706B1 BG 105539 A BG105539 A BG 105539A BG 10553901 A BG10553901 A BG 10553901A BG 64706 B1 BG64706 B1 BG 64706B1
Authority
BG
Bulgaria
Prior art keywords
eletriptan hydrobromide
eletriptan
monohydrate
hydrobromide monohydrate
water
Prior art date
Application number
BG105539A
Other languages
Bulgarian (bg)
English (en)
Other versions
BG105539A (en
Inventor
Christopher Dallman
Ronald Ogilvie
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of BG105539A publication Critical patent/BG105539A/xx
Publication of BG64706B1 publication Critical patent/BG64706B1/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Electroluminescent Light Sources (AREA)
  • Lasers (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
BG105539A 1998-11-27 2001-05-23 Елетриптан хидробромид монохидрат BG64706B1 (bg)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9825988.0A GB9825988D0 (en) 1998-11-27 1998-11-27 Indole derivatives

Publications (2)

Publication Number Publication Date
BG105539A BG105539A (en) 2001-12-29
BG64706B1 true BG64706B1 (bg) 2005-12-30

Family

ID=10843140

Family Applications (1)

Application Number Title Priority Date Filing Date
BG105539A BG64706B1 (bg) 1998-11-27 2001-05-23 Елетриптан хидробромид монохидрат

Country Status (53)

Country Link
US (2) US20020013358A1 (es)
EP (1) EP1135381B1 (es)
JP (1) JP3777094B2 (es)
KR (1) KR100413739B1 (es)
CN (1) CN1131860C (es)
AP (1) AP2001002149A0 (es)
AR (1) AR024232A1 (es)
AT (1) ATE273300T1 (es)
AU (1) AU754731B2 (es)
BG (1) BG64706B1 (es)
BR (1) BR9915692A (es)
CA (1) CA2352392C (es)
CO (1) CO5150178A1 (es)
CR (1) CR6325A (es)
CU (1) CU23269A3 (es)
CZ (1) CZ295472B6 (es)
DE (1) DE69919388T2 (es)
DK (1) DK1135381T3 (es)
DZ (1) DZ2948A1 (es)
EA (1) EA003551B1 (es)
EE (1) EE04914B1 (es)
ES (1) ES2224701T3 (es)
GB (1) GB9825988D0 (es)
GC (1) GC0000113A (es)
GE (1) GEP20043183B (es)
GT (1) GT199900202A (es)
HK (1) HK1042898B (es)
HN (1) HN1999000196A (es)
HR (1) HRP20010398B1 (es)
HU (1) HUP0105308A3 (es)
ID (1) ID28802A (es)
IL (1) IL141663A (es)
IS (1) IS2238B (es)
MA (1) MA26708A1 (es)
MY (1) MY124078A (es)
NO (1) NO320798B1 (es)
NZ (1) NZ510055A (es)
OA (1) OA11671A (es)
PA (1) PA8485701A1 (es)
PE (1) PE20001299A1 (es)
PL (1) PL194503B1 (es)
PT (1) PT1135381E (es)
RS (1) RS50002B (es)
SI (1) SI1135381T1 (es)
SK (1) SK285774B6 (es)
SV (1) SV1999000204A (es)
TN (1) TNSN99221A1 (es)
TR (1) TR200101493T2 (es)
TW (1) TWI246512B (es)
UA (1) UA68402C2 (es)
UY (2) UY25823A1 (es)
WO (1) WO2000032589A1 (es)
ZA (1) ZA200102681B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0018968D0 (en) * 2000-08-02 2000-09-20 Pfizer Ltd Particulate composition
WO2004089365A1 (en) 2003-04-11 2004-10-21 Pfizer Limited Pharmaceutical combination comprising eletriptan and sodium bicarbonate
US6927296B2 (en) 2003-07-23 2005-08-09 Pfizer Inc. Process
GB0317229D0 (en) * 2003-07-23 2003-08-27 Pfizer Ltd Improved process
EP2093225A1 (en) 2007-05-01 2009-08-26 Plus Chemicals B.V. Process for preparing crystalline eletriptan hydrobromide form ß
WO2008150500A1 (en) * 2007-05-29 2008-12-11 Plus Chemicals, S.A. A process for preparing 5-bromo-3-[(r)-1-methyl-pyrrolidin-2-ylmethyl]-1h-indole
WO2009077858A2 (en) * 2007-12-17 2009-06-25 Actavis Group Ptc Ehf Novel hemioxalate salt of eletriptan
US20120027816A1 (en) * 2009-02-25 2012-02-02 Actavis Group Ptc Ehf Highly pure eletriptan or a pharmaceutically acceptable salt thereof substantially free of eletriptan n-oxide impurity
WO2010116386A2 (en) * 2009-04-08 2010-10-14 Biophore India Pharmaceuticals Pvt. Ltd. Novel polymorph of eletriptan hydrobromide and process for the preparation thereof
US8754239B2 (en) 2010-01-19 2014-06-17 Sms Pharmaceuticals Limited Process for preparing eletriptan hydrobromide having α-form
WO2014063752A1 (en) 2012-10-26 2014-05-01 Synthon Bv Process for making crystalline form alpha of eletriptan hydrobromide
CN103893112A (zh) * 2012-12-31 2014-07-02 重庆圣华曦药业股份有限公司 氢溴酸依来曲普坦注射液
CN107954947A (zh) * 2016-10-14 2018-04-24 北京莱瑞森医药科技有限公司 沃替西汀氢溴酸盐晶型c及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3952741A (en) 1975-01-09 1976-04-27 Bend Research Inc. Controlled release delivery system by an osmotic bursting mechanism
FR2624732B1 (fr) 1987-12-21 1991-02-15 Synthelabo Formulation pharmaceutique a liberation prolongee
US5474784A (en) 1990-03-02 1995-12-12 British Technology Group Limited Dispensing device
RO111767B1 (ro) 1990-10-15 1997-01-30 Pfizer Derivati de indol, procedee si intermediari pentru prepararea acestora, compozitii farmaceutice si metoda pentru tratarea unor afectiuni
US5545644A (en) * 1990-10-15 1996-08-13 Pfizer Inc. Indole derivatives
US5464633A (en) 1994-05-24 1995-11-07 Jagotec Ag Pharmaceutical tablets releasing the active substance after a definite period of time
GB9417310D0 (en) * 1994-08-27 1994-10-19 Pfizer Ltd Therapeutic agents
GB9510223D0 (en) 1995-05-20 1995-07-19 Pfizer Ltd Therapeutic agent
TW448172B (en) * 1996-03-08 2001-08-01 Pharmacia & Upjohn Co Llc Novel hydroxamic acid derivatives useful for the treatment of diseases related to connective tissue degradation
US5998462A (en) * 1996-12-16 1999-12-07 Allelix Biopharmaceuticals Inc. 5-alkyl indole compounds
GB9704498D0 (en) * 1997-03-05 1997-04-23 Glaxo Wellcome Spa Chemical compound
US6166025A (en) 1997-07-03 2000-12-26 Pfizer Inc. Pharmaceutical compositions containing eletriptran hemisulphate and caffeine

Also Published As

Publication number Publication date
HUP0105308A3 (en) 2003-01-28
HRP20010398B1 (en) 2004-12-31
ATE273300T1 (de) 2004-08-15
HK1042898A1 (en) 2002-08-30
HUP0105308A2 (hu) 2002-05-29
IS5868A (is) 2001-02-27
SK6992001A3 (en) 2002-01-07
SV1999000204A (es) 2000-10-16
CU23269A3 (es) 2008-04-09
ES2224701T3 (es) 2005-03-01
EA003551B1 (ru) 2003-06-26
UY25825A1 (es) 2000-08-21
PE20001299A1 (es) 2000-12-01
GC0000113A (en) 2005-06-29
IL141663A0 (en) 2002-03-10
EP1135381A1 (en) 2001-09-26
MY124078A (en) 2006-06-30
BR9915692A (pt) 2001-08-14
RS50002B (sr) 2008-09-29
CR6325A (es) 2008-07-02
OA11671A (en) 2005-01-12
AR024232A1 (es) 2002-09-25
UA68402C2 (en) 2004-08-16
YU18801A (sh) 2003-07-07
UY25823A1 (es) 2001-08-27
WO2000032589A1 (en) 2000-06-08
PL194503B1 (pl) 2007-06-29
PL347928A1 (en) 2002-04-22
GEP20043183B (en) 2004-02-25
GT199900202A (es) 2001-05-19
CZ20011839A3 (cs) 2001-10-17
TWI246512B (en) 2006-01-01
EE200100285A (et) 2002-08-15
CA2352392A1 (en) 2000-06-08
EP1135381B1 (en) 2004-08-11
PA8485701A1 (es) 2000-09-29
TNSN99221A1 (fr) 2005-11-10
EA200100297A1 (ru) 2001-08-27
SK285774B6 (sk) 2007-08-02
JP3777094B2 (ja) 2006-05-24
GB9825988D0 (en) 1999-01-20
CZ295472B6 (cs) 2005-08-17
KR100413739B1 (ko) 2004-01-03
EE04914B1 (et) 2007-10-15
MA26708A1 (fr) 2004-12-20
JP2002531449A (ja) 2002-09-24
US20020013358A1 (en) 2002-01-31
NO320798B1 (no) 2006-01-30
BG105539A (en) 2001-12-29
CN1328554A (zh) 2001-12-26
CN1131860C (zh) 2003-12-24
ZA200102681B (en) 2002-07-02
TR200101493T2 (tr) 2002-02-21
HN1999000196A (es) 2005-11-26
AP2001002149A0 (en) 2001-06-30
CA2352392C (en) 2006-01-24
SI1135381T1 (en) 2004-10-31
PT1135381E (pt) 2004-10-29
DK1135381T3 (da) 2004-11-15
HK1042898B (zh) 2004-10-08
IS2238B (is) 2007-05-15
KR20010080594A (ko) 2001-08-22
DE69919388T2 (de) 2005-09-29
AU754731B2 (en) 2002-11-21
NZ510055A (en) 2004-11-26
DE69919388D1 (de) 2004-09-16
ID28802A (id) 2001-07-05
DZ2948A1 (fr) 2004-03-15
IL141663A (en) 2004-05-12
CO5150178A1 (es) 2002-04-29
NO20012584D0 (no) 2001-05-25
HRP20010398A2 (en) 2002-06-30
US20050131237A1 (en) 2005-06-16
NO20012584L (no) 2001-07-27
AU6225399A (en) 2000-06-19
US7238723B2 (en) 2007-07-03

Similar Documents

Publication Publication Date Title
US20070015841A1 (en) Pharmaceutical propylene glycol solvate compositions
BG64706B1 (bg) Елетриптан хидробромид монохидрат
JP3795395B2 (ja) 多形塩
US20060030602A1 (en) (S)-amlodipine malate
US8492423B2 (en) Pharmaceutical propylene glycol solvate compositions
HRP20000670A2 (en) Form vi 5,6-dichloro-2-(isopropylamino)-1-(beta-l-ribofuranosyl)-1h-benzimidazole
CN109721557A (zh) 来曲唑晶ii型固体物质及制备方法和其药物组合物与用途
MXPA01005313A (es) Derivados de indol
MXPA02008376A (es) Material cristalino.
WO2004076403A1 (en) Sumatriptan crystalline forms, pharmaceutical compositions and methods